Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Early TAP Block refers to a specific perioperative analgesic intervention developed and studied by William Beaumont Hospitals (now Corewell Health East) for managing postoperative pain in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). The intervention consists of a combination of ropivacaine, a long-acting local anesthetic, and dexamethasone, a corticosteroid used as an adjuvant to prolong the duration of the block. Ropivacaine works by inhibiting voltage-gated sodium channels in nerve fibers, thereby blocking the conduction of pain impulses. Dexamethasone is thought to enhance the block's efficacy through anti-inflammatory effects and potentially by direct action on glucocorticoid receptors in the nerves. In this specific protocol, the block is administered at the initiation of the surgical procedure (early) to provide preemptive analgesia, compared against a late administration at the conclusion of the procedure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + dexamethasone (Corewell Health).